Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with NamodenosonBusiness Wire • 01/31/22
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/17/22
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitroBusiness Wire • 01/13/22
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare ConferenceBusiness Wire • 01/10/22
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid TumorsBusiness Wire • 12/29/21
Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer PatientBenzinga • 12/20/21
CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher TodayInvestorPlace • 12/20/21
Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II StudyBusiness Wire • 12/20/21
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022Benzinga • 12/07/21
Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022Business Wire • 12/07/21
Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical UpdatesBenzinga • 11/26/21
Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical UpdateBusiness Wire • 11/26/21
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021Business Wire • 11/24/21
Can-Fite's Piclidenoson Commences Clinical Study for the Treatment of Canine OsteoarthritisBusiness Wire • 11/23/21
Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting® 2021 ConferenceBusiness Wire • 11/01/21